- One Year After Its Creation, OPM Continues to Successfully
Complete the Clinical Development of Its Drug Candidate OPM 101 and
Its Technological Platforms
- Cash position of € 9.5M to ensure the development of its
programs with financial visibility increased by 4 months since our
projections at the beginning of the year
- Revenues and operating income of €1.1 M for the first half
of 2023 (+121% vs. the first half of 2022 proforma), mainly driven
by its partnerships with US Company S-Engine and French group
Servier
- Net income of (€3.9) M due to its R&D expenses of €5 M
in the first half of 2023, mainly linked to the entry of OPM-101
into Phase I trials in healthy volunteers in February
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63;
Mnemonic: ALOPM), a biopharmaceutical company specializing in
precision medicine for the treatment of resistant and metastatic
cancer, announces its financial results for the first half of 2023,
approved by the Board of Directors on September 19, 2023.
Philippe GENNE, Chairman and CEO of Oncodesign Precision
Medicine (OPM), states: “OPM continues to strengthen its
construction, based on the integration of new skills and on its two
molecules currently in the clinic, and by providing itself the keys
to succeed in the future. The first half of 2023 was marked by the
fast progress of our 3 major programs: the entry into clinical
phase of OPM 101 in healthy volunteers in February this year, our
drug candidate directed against the RIPK2 kinase; its development
enabled us to successfully end the 1st part of this study and to
start the second part without losing any time. The same efficacy
applies to our collaborations with Servier Laboratories, with the
clinical trial of our LRRK2 kinase drug candidate started at the
end of 2022 and the "Start Pancreas" research partnership aimed at
discovering new therapeutic targets to treat pancreatic cancer. OPM
101 is our number 1 priority and represents high hopes for the
treatment of ulcerative colitis. RIPK2 is a new target that would
make OPM 101 the first immunomodulator in this field. This target
is also involved in oncology, and the development of followers and
other back-ups of OPM 101 offers a wide range of new opportunities.
We are very optimistic about the potential of our molecules to
continue successful development in their respective indications,
and about the relevance and productivity of our technologies."
Financial results for the first half of 2023
Oncodesign Precision Medicine - Income
Statement
in M€ Audited data
H1 - '23
H1 - '22 proforma
Evolution
In %
in value
Revenues
0.7
0.4
+ 70%
+ 0.3
Other revenues and operating
income
0.3
0.0
+ 636%
+ 0.3
Total revenues income and
operating income
1.1
0.5
+ 121%
+ 0.6
Purchases consumed
(4.0)
(3.4)
+ 18%
- 0.6
Personnel costs
(1.7)
(0.8)
+ 108%
- 0.9
Other operating expenses
(0.0)
(0.0)
- 100%
+ 0.0
Taxes and duties
(0.0)
(0.0)
+ 27%
- 0.0
Net changes in depreciation and
amortization
(0.1)
(0.1)
+ 72%
- 0.1
Total operating expenses
(5.9)
(4.3)
+ 36%
- 1.5
Operating result
(4.8)
(3.9)
+ 25%
- 0.96
Financial income and expenses
0.1
(0.1)
- 252%
+ 0.1
Income from ordinary activities
of consolidated companies
(4.7)
(3.9)
+ 21%
- 0.8
Extraordinary income and
expenses
0.0
-
na
+ 0.0
Income tax
0.8
0.7
+ 21%
+ 0.1
Net result
(3.9)
(3.3)
+ 21%
- 0.7
Preliminary statement: the accounts for the 1st half of 2022
presented here are proforma accounts, as OPM had not yet begun
operations at this time last year.
OPM revenues amounted to €0.7 M for the first half of 2023.
It includes revenues from our partnerships with the US company
S-Engine for €0.6 M and the French Servier Laboratories for €0.1 M.
These two partnerships respectively concern the discovery of a new
personalized treatment targeting metastatic tumors without
therapeutic solution in line with our strategy, and a strategic
collaboration for the discovery of new therapeutic targets in the
treatment of pancreatic cancer.
As expected, revenues for the first half of 2023 does not
include any milestones or up-fronts, which are by definition
non-recurring.
Management recalls that milestones and up-fronts constitute the
bulk of OPM's revenues, and that these revenues therefore fluctuate
greatly from one year to the next and are not the most relevant
indicator for judging the value of the company.
“Other income" of €0.3 M includes the Transition Service
Agreement (TSA) concluded with Oncodesign Services as part of the
demerger, and the sublease for headquarters offices. As a reminder,
the TSAs were cancelled at the end of the transition period, in
accordance with our agreements, and should generate almost no
revenues in the second half of 2023.
Our operating expenses amount to €4 M (+18%), which are mostly
subcontracting expenses. This increase is attributable to the
progress of our R&D program, and mainly to expenses associated
with phase 1 trial in healthy volunteers for OPM-101.
Regarding personnel costs, the difference between 2022 and 2023
is explained by the methodology used during the allocation of the
partial contribution of assets, the amount for the first half 2022
having been de facto increased by costs paid to ODS. The number of
employees fell slightly between the 2 financial years: OPM had 21
employees on June 30, 2023, compared to 22 employees at the same
date the previous year, and a freeze on salary increases was
decided at the beginning of 2023 for all employees.
OPM's income tax consists of the Research Tax Credit, which
increased by +21% to €0.8 M in the first half of 2023, in line with
the growth in R&D expenses eligible for this credit.
After considering financial and income expenses and
extraordinary income and expenses, that had a moderate impact of
€0.1 M, net result amounted to (€3.9) M.
R&D expenses for the first half of 2023
Oncodesign Precision Medicine - R&D
expenses
in M€ Analytical data
H1 - '23
H1 - '22 proforma
Evolution
In %
in value
Partnership programs
1.3
1.7
- 26%
- 0.5
Proprietary programs
3.7
2.1
+ 78%
+ 1.6
Total R&D expenses
5.0
3.8
+ 31%
+ 1.2
In the first half of 2023, R&D expenses amounted €5 M,
linked to the costs of the OPM-101 program, which alone accounts
for almost 36% of our total R&D expenses, currently in phase I
trial in Healthy Volunteers. For the record, this phase consists of
evaluating the tolerance of increasing doses in a single
administration, followed by repeated administrations.
At the same time, R&D expenses are also focused on the
ongoing development of the AI technology platform and its
collaborative program OncoSNIPE for the identification of targets,
program at the heart of the Drug Discovery partnership with SERVIER
(STarT Pancreas) to identify new therapeutic targets in pancreatic
cancer.
Cash position of €9.5 M as of June 30, 2023
This level of cash flow enables us to develop our OPM programs
with a 4-month improvement in cash flow compared with our prevision
at the beginning of the year, thanks to fine-tuned budget
management. This cash position includes the Research Tax Credit for
2022 received in June 2023 for €1.2 M, but does not include
potential future revenues, milestones and up-fronts. In addition,
various financing requests, including public programs, are in
progress and could significantly extend our cash horizon.
Intellectual property for our molecules
OPM is delighted to have received confirmation that its patent
on the general structure of OPM-101 and its analogues, derived from
its Nanocyclix® technology, has been extended to Europe, the United
States, China and Japan.
OPM share price
Despite a gloomy economic and stock market environment, OPM's
share price increased by +46% from €1.37 on June 21, 2023, to €1.99
at the opening on September 18, with an average of 12,000 shares
traded per day, reflecting investor confidence in our business
model and our pipeline of compounds now reaching maturity, with 2
compounds from Nanocyclix® in Phase I.
Corporate Social Responsibility
OPM has set up a major CSR program under the leadership of
Executive Management, to organize the company's workforce and
foster innovation, initiate research collaborations, mutualize
resources and co-develop tools and technologies. A collaboration is
currently under discussion with a healthcare establishment in Dijon
(France). OPM took part in, and won, the Odyssea race, a sporting
challenge to support the fight against breast cancer, held in Dijon
on June 6, 2023.
Publication of the financial report for the first half of
2023
The Financial Report for the first half of 2023 will be
available on the company's website www.oncodesign.comon Thursday September 28, 2023.
The limited review process on the consolidated financial statements
has been performed.
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers.
OPM's innovative technologies are (i) OncoSNIPER for the
selection of therapeutic targets using artificial intelligence;
(ii) Nanocyclix® for the design and selection of macrocyclic small
molecule kinase inhibitors and (iii) Theranostics for the design
and selection of radiolabeled biological molecules for systemic
radiotherapy.
From these technologies, OPM has built a portfolio of
therapeutic products. A first drug candidate based on the
Nanocyclix® technology entered the clinical phase in 2022, in
partnership with SERVIER (which exercised its option for an
exclusive worldwide license on the program) to treat Parkinson's
disease. ODS 101 is OPM's second candidate to enter the clinic, in
the treatment of chronic immuno-inflammatory diseases. Finally, OPM
is also collaborating with Servier to discover new therapeutic
targets for the treatment of pancreatic adenocarcinoma based on its
OncoSNIPER technology. In addition, OPM is seeking a partner for
Florepizol, a radiotracer specific for the mutated EGFR target,
which has successfully completed Phase I. Two projects are in early
partnership phase with TIUMBIO (pulmonary fibrosis) and SEngine in
oncology. Finally, OPM has a significant portfolio of early-stage
projects with Nanocyclix® and Theranostics in oncology. With this
portfolio of molecules and diversified therapeutic targets, OPM's
mission is to discover effective therapies to treat resistant and
advanced cancers. Based in Dijon, at the heart of the university
and hospital cluster, OPM has 25 employees.
More info at: oncodesign.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230919588640/en/
OPM Philippe Genne Chairman and Chief Executive Officer
Tel: +33 (0)3 80 78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
過去 株価チャート
から 4 2024 まで 5 2024
Oncodesign Precision Med... (EU:ALOPM)
過去 株価チャート
から 5 2023 まで 5 2024